-
May 9, 2018
Apotex Australia, an affiliate of Apotex Inc., headquartered in Toronto, Canada, today announced a proposed merger of their Australian and New Zealand generic pharmaceutical and over-the-counter (OTC) operations with Arrow Pharmaceuticals.
-
June 12, 2017
Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced their support of the Supreme Court decision in the Sandoz v Amgen case. The case clarifies the timing of the Biologics Price Competition and Innovation Act (BPCIA) requiring biosimilar companies to provide 180-days notice to the companies of the reference products of intent to market the biosimilar.
-
June 8, 2017
Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world are being honored at the annual Cooley's Anemia Foundation Gala tonight in New York City.
-
April 28, 2017
The University of Saskatchewan and Apotex Inc. have renewed their partnership with a $1.6 million donation by the company to the College of Pharmacy and Nutrition.
-
March 8, 2017
Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan
-
March 31, 2016
Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.
-
March 24, 2016
Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.